GlassScriptPhysician profile
Maria P Capo
NPI 1821199951
$9,200.47
in general payments reported to CMS, 2019-2025
31 companies · $1,975 in 2025
The $1,975 reported for 2025 was more than what 76% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,118 · 2020: $524 · 2021: $1,191 · 2022: $1,292 · 2023: $1,600 · 2024: $1,501 · 2025: $1,975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,884 · Education: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,883.74 |
| Education | $192.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,429.63 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $1,556.37 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Mylan Specialty L.P. | $1,164.66 | 2019-2024 | Yupelri, Yupelri |
| Philips North America LLC | $622.36 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $622.22 | 2019-2025 | Ofev, Jascayd |
| Viatris Specialty LLC | $350.09 | 2025 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $342.47 | 2019-2025 | Dupixent |
| Genzyme Corporation | $338.28 | 2019-2025 | |
| Insmed, INC. | $284.54 | 2020-2025 | Arikayce, Brinsupri |
| Inspire Medical Systems, INC. | $283.70 | 2022-2024 | Inspire |
| Sanofi-Aventis U.S. LLC | $184.94 | 2023-2024 | |
| Mallinckrodt Hospital Products INC. | $176.87 | 2020-2025 | Acthar |
| Electromed, INC. | $141.23 | 2019-2024 | Smartvest |
| Teva Pharmaceuticals USA, INC. | $110.82 | 2021-2022 | |
| Verona Pharma, INC. | $102.54 | 2025 | Ohtuvayre |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $68.99 | 2024-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| United Therapeutics Corporation | $64.59 | 2021-2025 | Tyvaso, Tyvaso |
| Novartis Pharmaceuticals Corporation | $60.18 | 2019-2023 | |
| Amgen INC. | $48.09 | 2024-2025 | Tezspire |
| Baxter Healthcare | $35.00 | 2022-2025 | Hillrom - Monarch Airway Clearance System |
| Grifols USA, LLC | $28.15 | 2019-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $26.31 | 2020-2022 | |
| Gilead Sciences, INC. | $25.89 | 2021 | |
| Optinose US, INC. | $22.39 | 2025 | |
| Advanced Respiratory, INC | $20.23 | 2021 | |
| Inogen, INC. | $19.75 | 2025 | |
| Azurity Pharmaceuticals, INC. | $16.28 | 2025 | Horizant |
| Mallinckrodt Enterprises LLC | $14.98 | 2019 | |
| Pfizer INC. | $13.79 | 2021 | |
| Resmed Corp | $13.66 | 2019 | |
| Shire North American Group INC | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Capo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.